AC
OCUL icon

Aristides Capital’s Ocular Therapeutix OCUL Stock Holding History

Aristides Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,226
Closed -$224K – 331
2023
Q4 		$224K Buy
+50,226
New +$149K 0.08% 189
2023
Q3 		– Sell
-35,000
Closed -$181K – 201
2023
Q2 		$181K Hold
35,000
– – 0.07% 140
2023
Q1 		$184K Buy
+35,000
New +$166K 0.1% 124
2022
Q1 		– Sell
-42,748
Closed -$298K – 265
2021
Q4 		$298K Buy
+42,748
New +$332K 0.14% 142

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Aristides Capital's OCUL Position: Q1 2024 in Review

Aristides Capital sold out of Ocular Therapeutix (OCUL) in Q1 2024, closing a stake of 50,226 shares — an estimated $224K sold.

Aristides Capital first reported a position in OCUL in Q4 2021 and held it in 4 quarters. The position peaked at $298K in Q4 2021. 148 funds tracked by Wall St. Rank hold OCUL as of Q1 2024.

  • Aristides Capital reported no remaining Ocular Therapeutix position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 50,226 Ocular Therapeutix shares in Q1 2024, an estimated $224K.
  • Aristides Capital first reported a position in Ocular Therapeutix in Q4 2021 and held it in 4 quarters.
  • Aristides Capital's Ocular Therapeutix position peaked at $298K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.